Coppell Advisory Solutions »

Lineage Cell Therapeutics In shares owned by Coppell Advisory Solutions

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Coppell Advisory Solutions from 13F filings

Historical chart of Coppell Advisory Solutions investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Coppell Advisory Solutions consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Coppell Advisory Solutions

Quarter filed Position value Share count Share price at filing
2023-12-31 $68 63 1.10
2023-09-30 $189 162 1.17
2023-06-30 $132 94 1.40
2022-12-31 $189 162 1.17

More positions owned by Coppell Advisory Solutions

First Tr Exchange Traded Fd Iv First Tr Enh New Etf FTSM (FTSM)
First Tr Exchange Traded Fd Vi Tcw Opportunis Etf Fixd (FIXD)
Microsoft Corp MSFT (MSFT)
Apple Aapl (AAPL)
Jp Morgan Chase & Co JPM (JPM)
Kingsmen Resources Ord KNG (KNG)
Spdr Series Trust Spdr Bloomberg Etf Bil (BIL)
Broadcom Avgo (AVGO)
Ishares Trust Short Treas Bd Etf SHV (SHV)
First Trust Large Cap Value Al Com Shs Etf Fta (FTA)
Ishares Trust Core S&p500 Etf Ivv (IVV)
First Trust Exchange-traded Fu Cap Strength Etf FTCS (FTCS)
Vaneck Vectors Etf Trust Invt Grade Fltg Etf FLTR (FLTR)
Vanguard S&p 500 Etf Voo (VOO)
First Tst Value Li Shs Etf FVD (FVD)

View all positions for Coppell Advisory Solutions

Top funds holding Lineage Cell Therapeutics In

Vanguard Group
Defender Capital
Raffles Associates
Prescott General Partners
MAI Wealth Advisors
Jpmorgan Chase & Co
Citadel Advisors
Laurion Capital Management
Charles Schwab Investment Management
Bank of New York Mellon
Long Focus Capital Management
Barclays
Royal Bank of Canada
Squarepoint Ops
Jane Street

View all funds holding Lineage Cell Therapeutics In